Topotecan
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Topotecan: From Ovarian Cancer to Female Breast Carcinoma
One-Sentence Summary
Topotecan is a topoisomerase I inhibitor established for treating relapsed ovarian cancer, small cell lung cancer, and cervical cancer. The TxGNN model predicts it may also be effective for Female Breast Carcinoma, with 5 clinical trials and 20 publications currently supporting this direction, though the evidence base remains at a moderate strength (L2).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Ovarian cancer, small cell lung cancer, cervical cancer (established oncology indications; no UK marketing-authorisation licence text is available in the current evidence pack) |
| Predicted New Indication | Female Breast Carcinoma |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L2 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for Topotecan is not available in this evidence pack (flagged as a High-severity data gap). Based on established pharmacological knowledge, Topotecan is a semisynthetic camptothecin derivative and topoisomerase I inhibitor. It works by stabilising the topoisomerase I–DNA cleavable complex, preventing DNA re-ligation and causing lethal double-strand breaks during replication in rapidly dividing cells. This broad-spectrum cytotoxic mechanism is not tumour-type specific, which is the pharmacological basis for exploring activity beyond its established indications.
Both the original indications (ovarian cancer, small cell lung cancer, cervical cancer) and the predicted new indication (female breast carcinoma) are solid tumours characterised by high proliferative activity, making them plausible targets for a topoisomerase I inhibitor. Multiple independent Phase II trials have directly enrolled breast cancer populations to test topotecan as monotherapy or in combination regimens, and this is consistent with the mechanistic hypothesis.
However, historical single-agent response rates for topotecan in breast cancer have been modest (approximately 2–11% in earlier trials), meaning that clinical benefit is more likely to depend on combination strategies (e.g., with paclitaxel, lapatinib, or novel agents targeting resistance mechanisms such as BCRP/P-glycoprotein) rather than monotherapy alone.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT02282020 | Phase 3 | Completed | 266 | Olaparib vs physician’s-choice single-agent chemotherapy in platinum-sensitive relapsed germline BRCA1/2-mutated ovarian cancer; population is ovarian cancer, relevance to breast cancer is uncertain (title truncated, graded B) |
| NCT04739800 | Phase 2 | Active, not recruiting | 120 | Durvalumab + olaparib + cediranib triplet therapy vs other combinations/standard chemotherapy in platinum-resistant recurrent ovarian, primary peritoneal or fallopian tube cancer previously treated with bevacizumab |
| NCT00006032 | Phase 2 | Terminated | N/A | TIME regimen (topotecan + ifosfamide/mesna + etoposide) followed by autologous stem cell rescue, designed specifically for metastatic breast cancer — direct disease-matched evidence |
| NCT02419495 | Phase 1 | Terminated | 221 | Selinexor combined with multiple standard chemotherapy/immunotherapy regimens (including topotecan) in advanced malignancies, with a breast cancer subgroup |
| NCT04279509 | N/A | Unknown | 35 | High-throughput drug-screen assay using patient-derived organoids to select chemotherapy (including topotecan) for refractory solid tumours; exploratory, non-therapeutic design |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10362325 | 1999 | RCT (Phase II) | American Journal of Clinical Oncology | CALGB Phase II trial of topotecan in advanced breast cancer following prior chemotherapy — direct disease-matched trial |
| 9626200 | 1998 | Phase II trial | Journal of Clinical Oncology | Paclitaxel + topotecan with G-CSF support in Stage IV breast cancer, with pharmacokinetic correlation to toxicity |
| 9413954 | 1997 | Phase II open-label trial | British Journal of Cancer | Continuous infusional topotecan in advanced breast cancer and NSCLC; no evidence of increased efficacy over standard schedules |
| 11455218 | 2001 | Pilot/cohort study | Onkologie | Topotecan chemotherapy in breast cancer patients with brain metastases |
| 40300683 | 2025 | Preclinical mechanistic study | International Journal of Biological Macromolecules | TFDP1 drives triple-negative breast cancer via senescence suppression and serves as a therapeutic target for topotecan |
| 27444351 | 2016 | Preclinical mechanistic study | Phytomedicine | MHP-1 restores topotecan sensitivity via regulating EMT and TGF-β signalling in breast cancer cells |
| 26623560 | 2015 | Preclinical study | Oncotarget | Metronomic topotecan + pazopanib combination shows potent efficacy in preclinical models of primary and metastatic triple-negative breast cancer |
| 31408695 | 2019 | Preclinical study | Pharmacological Research | Daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer |
| 15836850 | 2005 | Preclinical study | Journal of Surgical Research | Quercetin modulates topotecan cytotoxicity in MCF-7 and MDA-MB-231 breast cancer cell lines |
| 9445630 | 1997 | Review | Gynäkologisch-Geburtshilfliche Rundschau | Overview of new cytotoxic drugs, including topotecan, in the treatment of breast carcinoma |
UK Market Information
No UK marketing authorisation records are available in the current evidence pack. Topotecan is recorded as not marketed in this dataset, with zero licences on file. Internationally, topotecan is marketed (as Hycamtin and generics) for relapsed small cell lung cancer, metastatic ovarian carcinoma, and cervical cancer in combination with cisplatin; prescribers should consult the current UK SmPC/BNF entry directly for authorised indications and licensing status.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (topoisomerase I inhibitor, camptothecin derivative) |
| Myelosuppression Risk | High — dose-limiting neutropenia and thrombocytopenia are well documented across trials (e.g. PMID 8617580 reported median nadir neutrophil count 1.55 cells/mm³ and platelet count 20,500/mm³) |
| Emetogenicity Classification | Low to moderate, per standard chemotherapy antiemetic classification |
| Monitoring Items | Full blood count with differential (before each cycle and at nadir), renal function (topotecan is renally cleared), liver function |
| Handling Protection | Must be handled in accordance with cytotoxic drug handling regulations (hazardous drug precautions, closed-system transfer devices where available) |
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Several disease-matched Phase II trials and a growing body of preclinical mechanistic literature (including work on triple-negative breast cancer) support a plausible role for topotecan in breast carcinoma, but historical single-agent response rates are low and the drug currently has no UK marketing authorisation on file, so guardrails are needed before any clinical application is considered.
To proceed, the following is needed:
- Resolution of the Blocking data gap (DG001): TFDA/MHRA SmPC warnings and contraindications, required before any Stage 1 (S1) safety review can proceed
- Confirmation of detailed mechanism of action data (DG002) to strengthen the mechanistic-link analysis
- Verification of current UK licensing/import status, since this evidence pack records the drug as not marketed
- A combination-therapy strategy assessment, given the low historical single-agent response rate in breast cancer
- A drug interaction and monitoring plan, since no DDI records were found in this evidence pack
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.